Tilavonemab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameTilavonemab
Drug Alias NameTilavonemab - AbbVie/C2N DiagnosticsABBV-8E12C2N-8E12
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionMicrotubule-associated protein tau inhibitors
TargetsMicrotubule-associated protein tau
Therapy Area/IndicationsAlzheimer DiseaseSupranuclear Palsy, Progressive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[14] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesC2n Diagnostics Llc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesC2n Diagnostics Llc
Active IndicationsAlzheimer Disease
Inactive IndicationsSupranuclear Palsy, Progressive

Other Information

ATC CodeN/A
Related LinksN/A